JY
EPRS

Jeff Yass’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Jeff Yass’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-49,864
Closed -$446K – 10912
2015
Q1 		$446K Buy
+49,864
New +$401K ﹤0.01% 7308

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

Jeff Yass's EPRS Position: Q2 2015 in Review

Jeff Yass sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2015, closing a stake of 49,864 shares — an estimated $446K sold.

Jeff Yass first reported a position in EPRS in Q1 2015 and held it in 1 quarter. The position peaked at $446K in Q1 2015. 41 funds tracked by Wall St. Rank hold EPRS as of Q2 2015.

  • Jeff Yass reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2015 after selling out during the quarter.
  • Jeff Yass sold 49,864 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2015, an estimated $446K.
  • Jeff Yass first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 1 quarter.
  • Jeff Yass's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $446K in Q1 2015.
  • 41 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2015.

Based on Susquehanna International Group's 13F filing for Q2 2015, filed 14 Aug 2015.